ArticleIn silico pharmacology2025
Pentacyclo-icosan-19'-one compound from
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global resurgence of the monkeypox virus (MPXV) poses a serious threat to public health, necessitating the development of potent antiviral compounds. This study explored the potential of MPXV H1 phosphatase inhibitors using a computational biology approach, leveraging traditional knowledge from Indian Materia Medica. An in-house library of approximately 50,000 natural compounds from Indian Materia Medica was screened using molecular docking techniques, identifying 12,800 compounds with significant binding affinities, including ten hit compounds selected for further analysis. The top three hit compounds exhibited binding affinities as low as - 8.2 kcal/mol, surpassing the positive controls, Antimycin A (- 6.1 kcal/mol) and Tecovirimat (- 7.0 kcal/mol). These compounds were further optimized using Density Functional Theory (DFT), showing their significant electronic properties and redocked with the target. Molecular dynamics (MD) simulation demonstrated the structural stability of lead 3 and target complex over 200 ns with - 96.02 ± 1.00 kJ/mol binding energy, significantly outperforming the control Antimycin A (- 23.59 ± 2.97 kJ/mol) and Tecovirimat (- 49.07 ± 1.46 kJ/mol). These findings suggest that Lead 3 containing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.